Leening, Maarten J. G. http://orcid.org/0000-0002-4143-4839
Bouwer, Nathalie I.
Ikram, M. Arfan
Kavousi, Maryam
Ruiter, Rikje
Boersma, Eric
van den Bos, Ewout-Jan
Weevers, Auke P. J. D.
Deckers, Jaap W.
Levin, Mark-David
Clinical trials referenced in this document:
Documents that mention this clinical trial
Risk of cancer after ST-segment-elevation myocardial infarction
https://doi.org/10.1007/s10654-023-00984-8
Serum 25-hydroxyvitamin D3 is associated with advanced glycation end products (AGEs) measured as skin autofluorescence: The Rotterdam Study
https://doi.org/10.1007/s10654-018-0444-2
Dietary protein intake and all-cause and cause-specific mortality: results from the Rotterdam Study and a meta-analysis of prospective cohort studies
https://doi.org/10.1007/s10654-020-00607-6
Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
https://doi.org/10.1186/s12933-023-02052-7
Funding for this research was provided by:
Albert Schweitzer Hospital Research Fund (stipend 2018-05)
Foundation for Oncologic Research Albert Schweitzer (Project grant)
Foundation for Promoting Advanced Cardiology through Education (Project grant)
Article History
Received: 7 September 2022
Accepted: 28 February 2023
First Online: 22 March 2023
Declarations
:
: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Leening reports receiving speaker fees from Sanofi, and Novartis; and served on an advisory board for Boehringer Ingelheim; all unrelated to the submitted work. No other disclosures were reported.
: This study was approved by the Institutional Review Board of the Albert Schweitzer Hospital, Dordrecht (WOAC 2018.93), and the requirement for informed consent for the retrospective clinical cohort of STEMI patients was waived. The Rotterdam Study was approved by the Institutional Review Board of the Erasmus MC (MEC 02.1015) and by the Ministry of Health, Welfare, and Sport of the Netherlands, implementing the Population Screening Act: Rotterdam Study (license number 1071272-159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; ExternalRef removed) and into the WHO International Clinical Trials Registry Platform (ExternalRef removed) under shared catalogue number NTR6831. All Rotterdam Study participants provided written informed consent to participate and to obtain information from their treating physicians.